@entity2903 -loaded photopolymerizable XXXX -based hydrogel for the treatment of @entity463 .

@entity1 @entity1313 @entity19 @entity2904 @entity5 @entity59837 @entity2903 @entity463
UNASSIGNED: @entity463 is the most frequent primary @entity1313 in adults. Despite treatments including surgery, radiotherapy and chemotherapy by oral @entity2903 ( @entity2904 ), the prognosis of @entity1 with @entity463 remains very poor. We hypothesized that a @entity59837 ( @entity59837 ) injectable hydrogel would provide a sustained and local delivery of @entity2904 . The hydrogel photopolymerized rapidly (<2min) and presented a viscous modulus (   10kPa). @entity2904 release kinetic presented two phases: a linear burst release of 45% of @entity2904 during the first 24h, followed by a logarithmic release of 20% over the first week. The in vivo tolerability study showed that the unloaded hydrogel did not induce apoptosis in @entity19 brains nor increased microglial activation. In vivo, the anti- @entity5 efficacy of @entity2904 -hydrogel was evaluated on xenograft U87MG @entity5 -bearing @entity19 . The @entity5 weight of @entity19 treated with the photopolymerized @entity2904 hydrogel drastically decreased compared with all other groups. Higher apoptosis (located at the center of the @entity5 ) was also observed. The present study demonstrates the potential of a photopolymerizable @entity2904 -loaded hydrogel to treat @entity463 .
